The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Oncology Immuno Drug Market Research Report 2025
Synopsis
Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
The global Oncology Immuno Drug market was valued at US$ 2251 million in 2023 and is anticipated to reach US$ 3807.5 million by 2030, witnessing a CAGR of 8.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Oncology Immuno Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Immuno Drug.
Report Scope
The Oncology Immuno Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oncology Immuno Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Immuno Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol-Myers Squibb
Merck & Co
Roche AG
AstraZeneca
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
Segment by Type
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Other
Segment by Application
Hospitals
Drugstores
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oncology Immuno Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oncology Immuno Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
The global Oncology Immuno Drug market was valued at US$ 2251 million in 2023 and is anticipated to reach US$ 3807.5 million by 2030, witnessing a CAGR of 8.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Oncology Immuno Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Immuno Drug.
Report Scope
The Oncology Immuno Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oncology Immuno Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Immuno Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol-Myers Squibb
Merck & Co
Roche AG
AstraZeneca
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
Segment by Type
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Other
Segment by Application
Hospitals
Drugstores
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oncology Immuno Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oncology Immuno Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Oncology Immuno Drug Market Overview
1.1 Product Overview and Scope of Oncology Immuno Drug
1.2 Oncology Immuno Drug Segment by Type
1.2.1 Global Oncology Immuno Drug Market Value Comparison by Type (2024-2030)
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Cytokine-Based Immunotherapy
1.2.4 Cancer Vaccines
1.2.5 CAR-T Cell Therapy
1.2.6 Other
1.3 Oncology Immuno Drug Segment by Application
1.3.1 Global Oncology Immuno Drug Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Global Oncology Immuno Drug Market Size Estimates and Forecasts
1.4.1 Global Oncology Immuno Drug Revenue 2019-2030
1.4.2 Global Oncology Immuno Drug Sales 2019-2030
1.4.3 Global Oncology Immuno Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Oncology Immuno Drug Market Competition by Manufacturers
2.1 Global Oncology Immuno Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Oncology Immuno Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Oncology Immuno Drug Average Price by Manufacturers (2019-2024)
2.4 Global Oncology Immuno Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Oncology Immuno Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oncology Immuno Drug, Product Type & Application
2.7 Oncology Immuno Drug Market Competitive Situation and Trends
2.7.1 Oncology Immuno Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Oncology Immuno Drug Players Market Share by Revenue
2.7.3 Global Oncology Immuno Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Oncology Immuno Drug Retrospective Market Scenario by Region
3.1 Global Oncology Immuno Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Oncology Immuno Drug Global Oncology Immuno Drug Sales by Region: 2019-2030
3.2.1 Global Oncology Immuno Drug Sales by Region: 2019-2024
3.2.2 Global Oncology Immuno Drug Sales by Region: 2025-2030
3.3 Global Oncology Immuno Drug Global Oncology Immuno Drug Revenue by Region: 2019-2030
3.3.1 Global Oncology Immuno Drug Revenue by Region: 2019-2024
3.3.2 Global Oncology Immuno Drug Revenue by Region: 2025-2030
3.4 North America Oncology Immuno Drug Market Facts & Figures by Country
3.4.1 North America Oncology Immuno Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Oncology Immuno Drug Sales by Country (2019-2030)
3.4.3 North America Oncology Immuno Drug Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oncology Immuno Drug Market Facts & Figures by Country
3.5.1 Europe Oncology Immuno Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Oncology Immuno Drug Sales by Country (2019-2030)
3.5.3 Europe Oncology Immuno Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oncology Immuno Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Oncology Immuno Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Oncology Immuno Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Oncology Immuno Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Oncology Immuno Drug Market Facts & Figures by Country
3.7.1 Latin America Oncology Immuno Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Oncology Immuno Drug Sales by Country (2019-2030)
3.7.3 Latin America Oncology Immuno Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Oncology Immuno Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Oncology Immuno Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Oncology Immuno Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Oncology Immuno Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oncology Immuno Drug Sales by Type (2019-2030)
4.1.1 Global Oncology Immuno Drug Sales by Type (2019-2024)
4.1.2 Global Oncology Immuno Drug Sales by Type (2025-2030)
4.1.3 Global Oncology Immuno Drug Sales Market Share by Type (2019-2030)
4.2 Global Oncology Immuno Drug Revenue by Type (2019-2030)
4.2.1 Global Oncology Immuno Drug Revenue by Type (2019-2024)
4.2.2 Global Oncology Immuno Drug Revenue by Type (2025-2030)
4.2.3 Global Oncology Immuno Drug Revenue Market Share by Type (2019-2030)
4.3 Global Oncology Immuno Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Oncology Immuno Drug Sales by Application (2019-2030)
5.1.1 Global Oncology Immuno Drug Sales by Application (2019-2024)
5.1.2 Global Oncology Immuno Drug Sales by Application (2025-2030)
5.1.3 Global Oncology Immuno Drug Sales Market Share by Application (2019-2030)
5.2 Global Oncology Immuno Drug Revenue by Application (2019-2030)
5.2.1 Global Oncology Immuno Drug Revenue by Application (2019-2024)
5.2.2 Global Oncology Immuno Drug Revenue by Application (2025-2030)
5.2.3 Global Oncology Immuno Drug Revenue Market Share by Application (2019-2030)
5.3 Global Oncology Immuno Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bristol-Myers Squibb
6.1.1 Bristol-Myers Squibb Corporation Information
6.1.2 Bristol-Myers Squibb Description and Business Overview
6.1.3 Bristol-Myers Squibb Oncology Immuno Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bristol-Myers Squibb Oncology Immuno Drug Product Portfolio
6.1.5 Bristol-Myers Squibb Recent Developments/Updates
6.2 Merck & Co
6.2.1 Merck & Co Corporation Information
6.2.2 Merck & Co Description and Business Overview
6.2.3 Merck & Co Oncology Immuno Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck & Co Oncology Immuno Drug Product Portfolio
6.2.5 Merck & Co Recent Developments/Updates
6.3 Roche AG
6.3.1 Roche AG Corporation Information
6.3.2 Roche AG Description and Business Overview
6.3.3 Roche AG Oncology Immuno Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Roche AG Oncology Immuno Drug Product Portfolio
6.3.5 Roche AG Recent Developments/Updates
6.4 AstraZeneca
6.4.1 AstraZeneca Corporation Information
6.4.2 AstraZeneca Description and Business Overview
6.4.3 AstraZeneca Oncology Immuno Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 AstraZeneca Oncology Immuno Drug Product Portfolio
6.4.5 AstraZeneca Recent Developments/Updates
6.5 Sanofi S.A.
6.5.1 Sanofi S.A. Corporation Information
6.5.2 Sanofi S.A. Description and Business Overview
6.5.3 Sanofi S.A. Oncology Immuno Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Sanofi S.A. Oncology Immuno Drug Product Portfolio
6.5.5 Sanofi S.A. Recent Developments/Updates
6.6 Dendreon Pharmaceuticals
6.6.1 Dendreon Pharmaceuticals Corporation Information
6.6.2 Dendreon Pharmaceuticals Description and Business Overview
6.6.3 Dendreon Pharmaceuticals Oncology Immuno Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Dendreon Pharmaceuticals Oncology Immuno Drug Product Portfolio
6.6.5 Dendreon Pharmaceuticals Recent Developments/Updates
6.7 Novartis
6.6.1 Novartis Corporation Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Oncology Immuno Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis Oncology Immuno Drug Product Portfolio
6.7.5 Novartis Recent Developments/Updates
6.8 Gilead Sciences Inc.
6.8.1 Gilead Sciences Inc. Corporation Information
6.8.2 Gilead Sciences Inc. Description and Business Overview
6.8.3 Gilead Sciences Inc. Oncology Immuno Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Gilead Sciences Inc. Oncology Immuno Drug Product Portfolio
6.8.5 Gilead Sciences Inc. Recent Developments/Updates
6.9 Merck KGaA
6.9.1 Merck KGaA Corporation Information
6.9.2 Merck KGaA Description and Business Overview
6.9.3 Merck KGaA Oncology Immuno Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Merck KGaA Oncology Immuno Drug Product Portfolio
6.9.5 Merck KGaA Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oncology Immuno Drug Industry Chain Analysis
7.2 Oncology Immuno Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oncology Immuno Drug Production Mode & Process
7.4 Oncology Immuno Drug Sales and Marketing
7.4.1 Oncology Immuno Drug Sales Channels
7.4.2 Oncology Immuno Drug Distributors
7.5 Oncology Immuno Drug Customers
8 Oncology Immuno Drug Market Dynamics
8.1 Oncology Immuno Drug Industry Trends
8.2 Oncology Immuno Drug Market Drivers
8.3 Oncology Immuno Drug Market Challenges
8.4 Oncology Immuno Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
